Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...
A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...
In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...
In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community ...
U.S. District Judge Jesse Furman in Manhattan said UMB Bank was never properly appointed trustee for shareholders owning ...
Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback